Biotech Values

[WorstLuck]

GS removes ratings and price targets for early stage biotech

click through link (Sept 10, 2023) for pic of GS statement if it does not show.

Interesting move by Goldman, removing ratings & price targets until after phase 2. Why not just remove price targets in general? Most investors disregard them anyway and the approach by many sell side analysts is to adjust price targets after the fact. HT @Biotech_DD who I would… pic.twitter.com/kbsevuBVc9

— Daphne Zohar (@daphnezohar) September 10, 2023